Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors
April 08, 2024 12:00 ET
|
Mestag Therapeutics Ltd.
CAMBRIDGE, United Kingdom, April 08, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, is today presenting data...
Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting
March 05, 2024 16:30 ET
|
Mestag Therapeutics Ltd.
CAMBRIDGE, United Kingdom, March 05, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful...
Mestag Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
February 28, 2024 08:00 ET
|
Mestag Therapeutics Ltd.
CAMBRIDGE, United Kingdom, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful...
Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program
February 20, 2024 08:00 ET
|
Mestag Therapeutics Ltd.
CAMBRIDGE, United Kingdom, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful...